Skip to main content
TrialFinder
ResourcesAbout
Privacy policyTerms of useAccessibilityFAQFeedback
Support the project (opens in a new tab)

We use functional cookies to improve your experience. See our Privacy policy.

Trial data comes from ClinicalTrials.gov (US) and is shown for information only.

TrialFinder is not medical advice. Always talk with your doctor before deciding on a trial.

In memory of Dov Korn ❤️

AML (Acute Myeloid Leukemia) Clinical Trials | TrialFinder
HomeResourcesAML (Acute Myeloid Leukemia) Clinical Trials: FLT3, IDH, NPM1, and New vs Relapsed

Back to Resources

Published · September 27, 2026· Updated October 23, 2026

AML (Acute Myeloid Leukemia) Clinical Trials: FLT3, IDH, NPM1, and New vs Relapsed

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Its clinical trials are distinct from those for acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). For an AML trial search, the key details include whether the disease is newly diagnosed, relapsed or refractory, the mutation results, and whether intensive treatment is suitable.

A trial whose title says "leukemia" is usually written for only one of these. ALL, CML, and CLL studies are not interchangeable with AML studies. A report that only says "leukemia" is not enough to judge eligibility.

AML starts in the bone marrow, when myeloid cells grow out of control and crowd out healthy blood cells. Two people with AML can have different gene changes, a different disease setting (newly diagnosed versus relapsed or refractory), and a different fitness for intensive treatment. Those details usually decide which treatments are standard and which clinical trials may fit.

Genetic testing looks for changes such as FLT3 (including ITD and TKD), IDH1, IDH2, and NPM1. Some of these have approved targeted drugs in defined settings — FLT3 inhibitors such as midostaurin and gilteritinib, and IDH inhibitors such as ivosidenib (IDH1) and enasidenib (IDH2). Testing at diagnosis and again at relapse decides which targeted trials may fit. Ask for the mutation results by name.

A clinical trial is one option to raise with the treating hematologist. It is not automatically better than approved treatment. The useful question is whether a given study matches this exact diagnosis, mutation profile, disease setting, and whether intensive chemotherapy or transplant is on the table.

Newly diagnosed and relapsed/refractory AML are not interchangeable

First-line trials enroll people who have not yet been treated for AML, or who are starting initial therapy. Trials for relapse after treatment, and trials for disease that stopped responding (refractory), enroll different populations. The protocols are separate. A listing written for newly diagnosed AML is not the same as one for relapsed or refractory disease.

Cytogenetics and mutation results can also change between diagnosis and relapse. A mutation that was absent at diagnosis can appear later, and the reverse can happen after targeted therapy.

The plain-language clinical trial glossary can help with terms such as eligibility, phase, and standard of care.

Biomarkers that actually separate one trial from another

FLT3. FLT3 changes are common in AML. Two kinds appear on reports: ITD (internal tandem duplication) and TKD (tyrosine kinase domain). They are not interchangeable. Trials of FLT3 inhibitors, including drugs such as midostaurin and gilteritinib, usually name FLT3 and often name the exact kind.

IDH1 and IDH2. These are different genes. Ivosidenib is an IDH1 inhibitor. Enasidenib is an IDH2 inhibitor. A trial written for IDH1 is not an IDH2 trial. Ask which one, if either, is on the report.

NPM1. NPM1 mutations are also common in AML. Some targeted and combination trials require an NPM1 change, or pair it with FLT3 status. An NPM1 result by itself does not say which studies fit.

Genetic testing at diagnosis and at relapse is what decides which targeted trials belong on the shortlist. Ask the hematologist for the mutation results by name — FLT3 (ITD or TKD), IDH1, IDH2, NPM1 — not only whether "a mutation was found."

Some of these changes have approved targeted treatments in defined settings. Those approvals depend on the exact variant, whether disease is newly diagnosed or relapsed/refractory, prior treatment, the test that was used, and the country where care is given.

Fit and unfit AML are not the same trial lists

Many AML trials split by whether a person is considered eligible for intensive chemotherapy and stem cell transplant, or not. "Fit" and "unfit" (sometimes "older" or "ineligible for intensive therapy") are protocol terms. They change which studies apply.

Transplant-eligible, intensive-therapy trials often enroll younger or fitter adults and may include induction chemotherapy, consolidation, and allogeneic transplant pathways.

Lower-intensity trials enroll people for whom intensive chemotherapy or transplant is not the plan — because of age, other illness, or the hematologist's assessment. The drugs, visit burden, and eligibility cutoffs are different.

A report that only says AML does not say which of these lists to use. Ask whether intensive chemotherapy and transplant are being considered.

Recruiting AML trials

Questions to ask a hematologist

A short list is usually enough:

  • What is the exact diagnosis, including cytogenetics?
  • Were FLT3 (ITD and TKD), IDH1, IDH2, and NPM1 tested, and what were the results by name?
  • Is this newly diagnosed AML, or relapsed or refractory disease?
  • Is intensive chemotherapy and stem cell transplant being considered, or is the plan lower-intensity treatment?
  • For this profile, what is approved or considered standard where I live?
  • Are there recruiting trials that match this exact profile, and how do they differ from standard care?

Want to prepare for the appointment? The guide How to Talk to Your Doctor About Clinical Trials explains how to raise the topic and what to bring with you.

Sources

  • NCI: Leukemia
  • NCI PDQ: Adult AML treatment (patient)
  • NCI PDQ: Adult AML treatment (health professional)
  • Recruiting-trial facts on this page come from ClinicalTrials.gov and are shown through TrialFinder listings.

FAQ

What is AML, in plain language?

AML (acute myeloid leukemia) starts in the bone marrow, when myeloid cells grow out of control. Leukemia is not one disease. AML, ALL, CML, and CLL are different diseases with different treatments and different trial lists. This page is about AML, the most common acute leukemia in adults.

Why do newly diagnosed and relapsed or refractory AML matter for trials?

They are separate populations. First-line trials, trials for relapse after treatment, and trials for disease that stopped responding are written as different studies. A listing for newly diagnosed AML is not interchangeable with a relapsed or refractory study.

Which mutations separate AML trials?

Protocols often name FLT3 (including ITD and TKD), IDH1, IDH2, or NPM1. These changes can open targeted-therapy trials, such as FLT3 inhibitors like midostaurin and gilteritinib, or IDH inhibitors like ivosidenib and enasidenib. Ask for the results by name. Testing at diagnosis and again at relapse decides which targeted trials may fit.

Why does fit versus unfit change which AML trials apply?

Many AML trials split by whether a person is eligible for intensive chemotherapy and stem cell transplant (fit) or not (unfit, often older adults). The drugs, visit burden, and eligibility cutoffs are different. Ask the hematologist which path is being considered.

Do clinical trials replace approved AML treatment?

No. A trial is one option to discuss with a hematologist. It is not automatically better than approved treatment. What is considered standard depends on the exact diagnosis, mutations, disease setting, transplant eligibility, and country.

Further reading

How to Talk to Your Doctor About Clinical Trials What questions should you ask your doctor about clinical trials? A step-by-step guide for patients: when to bring it up, what to prepare, and what to do after.

Key Clinical Trial Terms Plain-language explanations of terms patients and families encounter during the clinical trial process.

Start Here: How to Search for Clinical Trials on TrialFinder A step-by-step guide to finding clinical trials on TrialFinder. Learn how to search by condition, use filters, and understand your results.

Before You Join a Clinical Trial: Screening, Informed Consent, and Red Flags Learn what screening and informed consent involve before you join a clinical trial, which questions to ask, and which red flags mean you should walk away.

ESMO 2026: Four Results You Can Act On Today Four ESMO 2026 results in lung cancer and melanoma with steps you can take now, from biomarker testing to open clinical trials.

Clinical Trials in Mental Health: What Patients and Families Should Know Mental health clinical trials may test medication, therapy, or devices. How they differ from cancer trials, and how to start looking.

The Reminder Moderna and Merck's Personalized mRNA Cancer Vaccine Gives Us About Clinical Trials Moderna and Merck's personalized mRNA vaccine met Phase 3 goals in melanoma. What that shows about joining a clinical trial.

Daraxonrasib (RASONQUE) Is Now FDA-Approved for Metastatic Pancreatic Cancer The FDA approved daraxonrasib (RASONQUE) on August 26, 2026 for metastatic pancreatic cancer after prior therapy.

What is a Clinical Trial? (It's More Than You Think) How clinical trials work, why they matter, and what patients should know before considering one.

Not a Perfect Match? Tips for Getting Into a Clinical Trial Anyway A rejection from a clinical trial doesn't have to be the end. Practical tips for patients and caregivers who hit a wall.

How to Talk About Clinical Trials with a Family Member A guide for caregivers on introducing clinical trials to a loved one who is hesitant, tired, or afraid.

Share this post
  •  

This article was written by a patient advocate based on personal experience, not by a medical professional. It is not medical advice. Consult your doctor before making any medical decisions.

Looking for a clinical trial?

Search trials

Trial data from ClinicalTrials.gov. For information only.

This list is limited to recruiting studies whose title or listed conditions name AML or acute myeloid leukemia. A biomarker or setting heading appears only when that term is named in those same fields. A listing that only says leukemia, without naming AML, is not included — those studies are usually written for a different leukemia type.

Intensity

Biomarker

Setting

Loading matching clinical trials

Trials whose title or listed conditions name FLT3

  • ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    Acute Myeloid Leukemia · Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia

    United StatesRecruitingPhase 1/2
    Simple summary·Eligibility check·Doctor guide
    Houston, United States
  • HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

    Leukemia, Acute Myeloid (AML)

    ChinaRecruitingPhase 3
    Simple summary·Eligibility check·Doctor guide
    Hanzhou, China
  • CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

    Acute Myeloid Leukemia in Children

    NetherlandsRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Utrecht, Netherlands

Trials whose title or listed conditions name IDH1

  • Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

    AML · IDH1 Mutation · Treatment

    ChinaRecruitingPhase 1/2
    Simple summary·Eligibility check·Doctor guide
    Tianjin, China
  • Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

    Acute Myeloid Leukemia · IDH1 Mutation

    United StatesRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Miami, United States

Trials whose title or listed conditions name NPM1

  • Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions

    Acute Myeloid Leukemia · NPM1 Mutation

    ItalyRecruiting
    Simple summary·Eligibility check·Doctor guide
    Florence, Italy
  • A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

    Acute Myeloid Leukemia (AML)

    JapanRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Chiba, Japan · Gifu, Japan

Trials whose title or listed conditions name newly diagnosed AML

  • A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

    Acute Myeloid Leukemia

    United StatesRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Basking Ridge, United States · Middletown, United States
  • Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

    Newly Diagnosed Acute Myeloid Leukemia (AML) · Elderly Patients

    ChinaRecruitingPhase 3
    Simple summary·Eligibility check·Doctor guide
    Beijing, China
  • IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

    Acute Myeloid Leukemia

    United StatesRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Aurora, United States · Chapel Hill, United States
  • CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

    Acute Myeloid Leukemia

    FranceRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Amiens, France · Angers, France
  • Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML

    Acute Myeloid Leukemia

    ChinaRecruitingPhase 2/3
    Simple summary·Eligibility check·Doctor guide
    Suzhou, China

Trials whose title or listed conditions name relapsed or refractory AML

  • Explained in plain language

    Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

    Acute Myeloid Leukemia · Myelodysplastic Syndrome · Myelodysplastic Syndrome/Acute Myeloid Leukemia

    United StatesRecruitingPhase 1
    Simple summary·Eligibility check·Doctor guide
    New Haven, United States · Atlanta, United States
  • Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

    Refractory Acute Myeloid Leukemia · Relapsed Acute Myeloid Leukemia · Acute Leukemia of Ambiguous Lineage

    United StatesRecruitingPhase 1
    Simple summary·Eligibility check·Doctor guide
    San Diego, United States · Aurora, United States
  • Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia

    AML (Acute Myelogenous Leukemia · Relapsed Acute Myelogenous Leukemia · Refractory Acute Myeloid Leukemia

    ChinaRecruitingPhase 1
    Simple summary·Eligibility check·Doctor guide
    Hangzhou, China
  • Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN

    AML (Acute Myeloid Leukemia) · BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm)

    ChinaRecruitingPhase 1
    Simple summary·Eligibility check·Doctor guide
    Wuhan, China
  • CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

    Acute Myeloid Leukemia, Adult · Acute Myeloid Leukemia Recurrent · Acute Myeloid Leukemia, Relapsed, Adult

    United StatesRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Baltimore, United States
  • Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

    Acute Leukemia · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia

    United StatesRecruitingPhase 2
    Simple summary·Eligibility check·Doctor guide
    Minneapolis, United States
  • A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

    Acute Myeloid Leukemia · Mixed Lineage Leukemia Gene Mutation · Refractory AML

    United StatesRecruitingPhase 1
    Simple summary·Eligibility check·Doctor guide
    Phoenix, United States · La Jolla, United States
  • PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

    Acute Myeloid Leukemia · Acute Myeloid Leukemia Refractory · Acute Myeloid Leukemia, in Relapse

    United StatesRecruitingPhase 1
    Simple summary·Eligibility check·Doctor guide
    Seattle, United States

Open the full TrialFinder search for AML